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The aim of this study was to establish mitochondrial cholesterol trafficking 18kDa translocator protein 
(TSPO) as a potential therapeutic target, capable of increasing macrophage cholesterol efflux to 
(apo)lipoprotein acceptors.   
Expression and activity of TSPO in human (THP-1) macrophages were manipulated genetically, and 
by the use of selective TSPO ligands.  Cellular responses were analysed by quantitative PCR, 
immunoblotting and radiolabelling, including [
3
H]cholesterol efflux to apoA-I, HDL and human 
serum.   
Induction of macrophage cholesterol deposition by acetylated LDL (AcLDL) increased expression of 
TSPO mRNA and protein, reflecting findings in human carotid atherosclerosis.  Transient 
overexpression of TSPO protein enhanced efflux (E%) of [
3
H]cholesterol to ApoA-I, HDL and human 
serum, compared with empty vector controls, while gene knockdown of TSPO achieved the converse.  
Ligation of TSPO (PK11195, FGIN-1-27, flunitrazepam) triggered increases in [
3
H]cholesterol efflux, 
an effect which was amplified in TSPO overexpressing macrophages.  Overexpression of TSPO 
induced expression of genes (PPARA, NR1H3, ABCA1, ABCG4, APOE) and proteins (ABCA1, 
PPAR) involved in cholesterol efflux, reduced macrophage neutral lipid mass and lipogenesis, and 
limited cholesterol esterification following exposure to AcLDL.    Thus, targeting TSPO reduces 
macrophage lipid content and prevents macrophage foam cell formation, via enhanced cholesterol 
efflux to (apo)lipoprotein acceptors.   
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Mitochondrial dysfunction, associated with increased production of reactive oxygen species, 
accumulation of mitochondrial DNA damage and progressive loss of respiratory chain function, is 
found in atherosclerotic lesions in both human studies, and in animal models of atherogenesis
1
.  
Oxidized low density lipoprotein (OxLDL), ageing, hyperhomocysteinaemia, hyperglycaemia, 
hypertriglyceridaemia, type 2 diabetes mellitus and cigarette smoking are all associated with 
mitochondrial damage and increased production of reactive oxygen species
2-4
.  Increased arterial 
oxidative stress modifies LDL to a form recognised by macrophage scavenger receptors, resulting in 
further mitochondrial damage, and the unregulated accumulation of excess cholesterol and cholesteryl 
esters within macrophage ‘foam cells’, hallmark of early and developing atheroma1-5.  Reversal of this 
process, regressing and stabilising atherosclerotic lesions, can be effected by efficient removal of 
cholesterol from ‘foam cells’, to acceptor particles such as apolipoprotein (apo) A-I,  apoE or nascent 
high density lipoproteins (HDL), which then enter the athero-protective reverse cholesterol transport 







, demonstrated that overexpression of mitochondrial cholesterol trafficking 





 and increases macrophage cholesterol efflux
7,8
, while a viral vector 




.   Overexpression of StAR 
enhances the rate-limiting step in mitochondrial generation of oxysterol ligands for LXR: transfer 
of cholesterol to sterol 27-hydroxylase (CYP27A1) located on the inner mitochondrial membrane
10,11
.  
Sterol 27-hydroxylase generates oxysterol ligands for Liver X Receptors (LXR), nuclear 
transcription factors which regulate gene expression of proteins involved in the cholesterol efflux 
pathway, including ATP binding cassette transporters, ABCA1, ABCG1/ABCG4, which orchestrate 
transfer of cholesterol and/or phospholipids across the plasma membrane to (apo)lipoproteins, such as 
apoA-I and apoE
12-14
.   Loss of CYP27A1 results in cerebrotendinous xanthomatosis, which can be 
characterised by increased risk of premature atherosclerosis, despite normal circulating concentrations 
of plasma LDL
15
.   Exploiting the anti-atherogenic functions of StAR may prove problematic, 
however, due either to induction of lipogenesis
7
 or the dearth of small molecules capable of 
modulating the activity of this protein in vivo.   
However, StAR interacts with a protein complex, located at contact sites between outer and inner 
mitochondrial membranes, which includes 18kDa translocator protein (TSPO/peripheral 
benzodiazepine receptor/PBR), voltage dependent anion channel (VDAC) and adenine nucleotide 
transporter (ANT), and associated proteins, including cAMP-dependent protein kinase associated 
protein (PAP7/ Acyl CoA binding domain-3/ACBD3), PBR-associated protein (PRAX1) and its 
proposed endogenous ligand, diazepam binding inhibitor (DBI/ACBD1)
16,17
.   The translocator protein 




has five transmembrane domains, and a high affinity cholesterol recognition amino acid (CRAC) 
binding C-terminal domain
16, 17
; the CRAC peptide was recently used as an interchelating agent to 




.  Knockdown of TSPO induces arrest of 
mitochondrial cholesterol transport, which can be rescued by TSPO cDNA, while global deletion of 
TSPO is embryonic lethal in mice
16, 17
.   Intriguingly, TSPO ligands were recently shown to activate 
fasting metabolism, reducing lipogenesis and hepatosteatosis in obese mice
19
, suggesting that 
additional activities associate with this protein.   
The contribution, and therapeutic potential, of TSPO and associated proteins in regulation of the 
cholesterol efflux pathway in macrophages and macrophage ‘foam cells’, remains uninvestigated, 
despite the potential importance of this pathway in activating the anti-atherogenic cholesterol efflux 
process. Here, we study gene and protein expression of TSPO during macrophage ‘foam cell’ 
formation, and demonstrate the positive impact of TSPO overexpression and/or ligation on 
macrophage cholesterol efflux;  notably, TSPO overexpression causes a decline in macrophage total 
neutral lipid mass, without induction of lipogenesis, and effectively prevents ‘foam cell’ formation 
following exposure to acetylated LDL. We postulate that existing ligands for TSPO may possess anti-
atherosclerotic properties, readily amenable to testing in clinical studies.   
Methods 
2.1 Materials  Human monocytic cell line (THP-1) and murine RAW264.7 macrophages 
were purchased from the European Cell Culture Collection (Porton Down, UK).   Cryopreserved 
human peripheral blood monocytes (10
7
) isolated from fresh blood were purchased from Promocell 
(UK distributors); the sample of total RNA (50g) derived from normal human aortas pooled from 4 
male/female Caucasians (aged 27-45) who died of sudden death, was purchased from Clontech 
Laboratories Inc. (CA, USA).   Tissue culture reagents were purchased from Lonza (Wokingham, 
UK); other sources include Amaxa Transfection reagent (Lonza, UK), NuPage gels and buffers (Life 
Technologies, Paisley, Scotland), antibodies (AbCAM, Cambridge, UK) and primers and probes 
(Eurogentec, Belgium).  Apolipoprotein A-I, high density lipoprotein (HDL) and low density density 
lipoprotein (LDL) were purchased from Athens Research UK (USA); LDL was acetylated according 
to Brown et al
20




C]acetic acid and [
3
H]oleic acid) were provided 
by ICN Biologicals; all other chemicals were provided by Sigma-Aldrich (Poole, Dorset, UK).  
Mammalian expression vectors (pCMV6) encoding TSPO, DBI, VDAC and ANT were supplied by 
Origene, via Cambridge Biosciences (UK); TriFecta Dicer Substrate RNAi duplexes directed against 
TSPO and scrambled control sequences were supplied by Integrated DNA Technologies (IDT, 
Germany).  We are greatly indebted to Professor D.J. Mangelsdorf (South Western Medical Center, 
USA) for his kind gift of LXRE reporter plasmid (pCMX.LXRE).   




2.2 Cell culture Human THP-1 monocytes were maintained using a split ratio of 1:10 in 
RPMI medium supplemented with foetal bovine serum (FBS, 10%, v/v), L-glutamine (200mM) and 
penicillin/streptomycin (50 g ml-1; 50 U ml-1, respectively).  For experiments, cells were plated onto 




, in complete RPMI medium (above) 
supplemented with 100nM phorbol 12-myristate 13-acetate (PMA) to induce macrophage 
differentiation.  Transfection of monocytes, immediately prior to differentiation, was achieved using 
the ‘Human Monocyte’ transfection reagent (VPA-1007) and electroporation protocol (Y001), as per 
manufacturer’s instructions (Amaxa, Lonza), and as previously described21; our studies have 
established a transfection efficiency of 70-80%, without significant (<5%) loss of cell viability, using 
this system.  Mammalian expression vector pCMV.6_TSPO (0.5g) was used to transiently (48h) 
overexpress the mitochondrial translocator protein, while validated siRNA (10nM) duplexes directed 
against TSPO and PPARA were used for gene knockdown (48h).  Transient transfections were also 
performed using the same quantities of vector encoding full length VDAC, ANT and DBI.  The empty 
vector (pCMV6), and scrambled siRNA sequences of the same nucleotides, were used as respective 
controls.  Macrophages were treated with TSPO ligands for 48h prior to assessment of cholesterol 
efflux, using DMSO (<0.01%) as vehicle.  Transient expression of pCMX.LXRE (0.5g) was achieved 
using Fugene6 (6l: 1g DNA; 24h) and luciferase activity determined (Britelite Plus, Perkin Elmer) 
as previously described
7,22, 23
. Cell viabilities were determined by conversion of methyl thiazolyl blue 
tetrazolium bromide to formazan, as previously
7,22, 23
. 
2.3 Macrophage lipid analysis and cholesterol efflux    Incorporation of [
14
C]acetic acid 
(1Ci ml-1; 24h) into fatty acid, phospholipid, cholesterol, cholesteryl ester and triacylglycerol pools 
was initiated 48h post-transfection, and as previously described
7,22,23
.  Esterification of cholesterol, in 
the presence of acetylated LDL (50 g ml-1) was monitored by flux of [3H]oleic acid (1M, 1Ci ml-
1
) into cholesteryl [
3
H]oleate, as previously described
7,20,22,23
.  Macrophage lipids were extracted using 
hexane:isopropanol (3:2, v/v) and dried under nitrogen, before separation by t.l.c., using the mobile 
phases described
7,20,22,23
.  Lipids were identified by co-migration with authentic standards, 
incorporation of radiolabel determined by scintillation counting, with data expressed as nmol 




C]oleic acid (3M; 0.15 Ci ml-1) 
was assessed as previously described
24
.  Neutral lipid mass (total cholesterol, triacylglycerol) in 
macrophage lipid extracts (above) were determined using colorimetric assays (Infinity™), and 
expressed as g lipid per mg cell protein7, 20,22,23.    Macrophage efflux of [3H]cholesterol to apoA-I 
(20 g ml-1), HDL (20 g ml-1) and human serum (1%, v/v) were determined as previously 
described
22,23
.  Efflux (24h) from radiolabelled macrophages was initiated 48h post-transfection by 
addition of serum-free RPMI containing each acceptor, and results are expressed as % cholesterol 
efflux, calculated as [dpmmedia/dpm(media + cells)] x 100%.    




2.4 Analysis of gene and protein expression  Total RNA was isolated (TriFast, Peqlabs) 
from macrophages and reverse transcribed to cDNA (BioLine, UK) prior to measurement of cellular 
levels of mRNA encoding the mitochondrial cholesterol trafficking complex (TSPO, VDAC, ANT), 
lipid responsive transcription factors (SREBF1, SREBF2, PPARA, PPARG, PPARD, NR1H3) and key 
elements of the cholesterol efflux pathway (ABCA1, ABCG1, ABCG4, APOE).   Quantitative 
polymerase chain reaction (Q-PCR), relative to GAPDH, was performed using the primers and 
fluorescent (FAM/TAMRA) probe sequences indicated in Table 1 (Supplementary Data); negative 
reverse transcription controls were performed for all samples.   Gene expression of an array of 84 
genes implicated in atherosclerosis were analysed in control and TSPO overexpressing macrophages 
using the RT
2
 Profiler Human Atherosclerosis PCR array (Qiagen; PAHS-038A).   Assessment of 
CPT-1A gene expression was performed using forward (ACAGTCGGTGAGGCCTCT TATGAA) 
and reverse primers (TCTTGCTGCCTGAATGTGAGTTGG), generating a 252 bp product, semi-
quantified by densitometry using a GelDoc XR.   
Macrophage cell lysates were prepared in RIPA buffer (25mM Tris HCl pH 7.6, 150mM NaCl, 1% 
(v/v), NP-40, 1% (w/v) sodium deoxycholate, 0.1% (w/v) sodium dodecyl suphate) supplemented 
with Complete™ protease inhibitor cocktail (Roche), and proteins (20-50g lane-1)  separated using 
NuPAGE (10%, w/v) gels.  Transfer to a PDVF membrane was followed by immunoblotting using 
rabbit polyclonal antibodies (1:1000 dilution) against ABCA1 TSPO, PPAR, ACAT1 and GAPDH 
(1:2000) and detection achieved for the majority of the data presented, using secondary antibodies 
coupled to the ECL detection system, as previously described
7,22,23
.   Densitometry was performed 
using a GelDoc XR using Image Lab Software for Western Blot Analysis (Biorad, UK).  However, 
the images presented for SiRNA knockdown of TSPO in Figure 2A, and for PPARfollowing TSPO 
overexpression in Figure 5B were detected using a donkey anti-rabbit secondary antibody (1:12,500) 
labelled with IRDye® 800CW (LI-COR Biosciences UK Ltd) and the LI-COR Odyssey Fc Imaging 
System with LI-COR Image Studio version 3.1.4 software.  
All values are mean±SEM, with numbers of independent experiments denoted by n.  Significant 
(p<0.05) differences were determined using Student’s t-test, or by employing analysis of variance 
(ANOVA) and post t-tests, as indicated in the Legends to Figures.    
Results 
An indication of the levels of gene expression of TSPO, VDAC and ANT, relative to the housekeeping 
gene GAPDH, in peripheral blood monocytes and in normal heart aorta are shown in Figure 1A, to 
provide a physiological context and comparison for the studies carried out using macrophages derived 
from the human THP-1 monocytic cell line; mRNA levels of these genes in differentiated THP-1 
macrophages and THP-1 macrophage ‘foam cells’ are shown in Figure 1B.    Exposure of THP-1 




macrophages to two doses of 50 g ml-1 AcLDL (24h), led to a modest but significant increase (27%; 
p<0.05) in total cholesterol mass (control 58.0+1.7 g mg-1 cell protein versus AcLDL 73.7+7.2 g 
mg
-1
 cell protein; p<0.05; n=4), a mild cholesterol loading condition that avoids the overt toxicity 
associated with exposure to higher concentrations of modified LDL
25
.  Levels of mRNA encoding 
TSPO were increased by 1.8±0.3-fold following exposure to AcLDL, reflected in increased levels of 
TSPO protein (37%; p<0.05; n=3), relative to VDAC or GAPDH (Figure 1B).  Analysis 
(MatInspector) of the -3kb upstream promoter region of TSPO revealed a number of putative 
transcription factor binding sites, including sterol regulatory elements (-2113-2097; -1957-1922; -
1783-1769) and peroxisome proliferator activated receptor (PPAR) responsive elements (-2214-2191; 
-366-344). 
Overexpression and gene knockdown of TSPO in THP-1 macrophages: impact on cholesterol 
efflux 
Overexpression and knockdown of dimeric TSPO protein (44kDa) relative to GAPDH, and compared 
with the empty vector controls (EV; pCMV.6) or SiRNA negative control, are shown in Figure 2A 
and 2B, measured as detailed in the Methods.   No changes in cell viability were associated with 
TSPO overexpression (EV 37.8±0.9 M formazan versus TSPO 36.2 ±0.9 M formazan, n=3; NS).  
Overexpression of TSPO significantly increased efflux (24h), of [
3
H]cholesterol, to 20 g ml-1 ApoA-
I (60±27.4%; p<0.01; n=3), 20 g ml-1 HDL (74± 13.2%; p<0.05) and 1% (v/v) human serum 
(51.7±21.2%; p<0.05; n=3) (Figure 2C), when compared with cells transfected with the empty 
vector.   Conversely, gene knockdown of TSPO subsequently reduced [
3
H]cholesterol efflux (24h) to 
ApoA-I  (20 g ml-1) and HDL (20 g ml-1) by 15.7±5.7% (p<0.05) and 14.3±9.2% (p<0.05), 
respectively, when compared with the scrambled SiRNA negative control (Figure 2D).  
Transfection with the same quantity of vector encoding the proposed endogenous ligand for TSPO, 
DBI induced a small increase in efflux to apoA-I, which did not quite reach significance (EV 
5.1±0.78% versus DBI 6.4±0.3%; p=0.06; n=3), but did significantly (p<0.01) increase efflux of 
[
3
H]cholesterol to HDL (EV 19.8±1.8% versus DBI 21.3±1.9%; n=3).  By contrast, equivalent 
transfections with vector encoding either VDAC or ANT, did not significantly alter efflux of 
[
3
H]cholesterol to either apoA-I (EV 4.0±0.2% versus VDAC 4.2±0.3% versus ANT 4.4±0.4%; NS; 
n=3) or HDL (EV 8.8±0.7% versus VDAC 8.8±0.8% versus ANT 9.7±0.8%; NS; n=3), when tested 
under the same conditions.   
Ligation of TSPO increases macrophage cholesterol efflux to apoA-I and HDL 
Wild type THP-1 macrophages were treated with established TSPO ligands, PK11195, FGIN-1-27 
and flunitrazepem, using concentrations commonly utilised to increase mitochondrial cholesterol 
trafficking and steroidogenesis 
16, 17
.    Significant increases in [
3
H]cholesterol efflux to apoA-I (20g 






; Figure 3) were noted following treatment with PK11195 (30M; p<0.05; n=3), flunitrazepam 
(30M; p<0.01; n=3) and FGIN-1-27 (10M; p<0.05; n=3) (Figures 3A, 3B and 3C).  By contrast, 
only PK11195 (p<0.01; n=3) and FGIN-1-27 (p<0.01; n=3) increased efflux of cholesterol to HDL 
(20g ml-1) (Figures 3A, 3B and 3C).   Notably, in macrophages overexpressing TSPO, treatment 
with FGIN-1-27 increased efflux to apoA-I by a further 2.2±0.2-fold (p<0.001; n=3) resulting in a 
5.2±0.6 fold (p<0.001; n=3) increase in efflux above basal levels (Figure 3D).   Equally, knockdown 
of TSPO abrogated the stimulatory (31.7±8.6%) effect of FGIN-1-27 (10M) on cholesterol efflux to 
apoA-I (scrambled control 8.3±0.7% versus siRNA to TSPO 6.8±0.6%; p<0.05; n=3). 
Overexpression of TSPO: impact on lipid phenotype 
Transient TSPO overexpression (48h) was associated with a marked loss of macrophage neutral lipid 
mass, due to reductions in total cholesterol (52.6±8.9%; p<0.05, n=4) and triacylglycerol 
(34.2±10.9%; p<0.05, n=4) content (Figure 4A).  However, we previously reported that 
overexpression of mitochondrial cholesterol trafficking protein, steroidogenic acute regulatory protein 
(StAR; STARD1) is associated with induction of lipogenesis in macrophages
7
.   Accordingly, we 
investigated the impact of transient TSPO overexpression (48h) on the subsequent incorporation of 
[
14
C]acetate into macrophage lipid pools (24h) (Figure 4B).  A small reduction in total lipogenesis 
(10±3.1%; p<0.05; n=6) was noted, predominantly due to a 15±6.2% (p<0.05; n=6) reduction in 
incorporation of [
14
C]acetate into the fatty acid pool.    Increased oxidation of [1-
14
C]oleic acid, 
expressed as a percentage of cellular uptake, (EV 0.30±0.03% h
-1 
versus TSPO 0.52±0.05% h
-1
; 
p<0.05; n=3), was associated with a 2-fold induction of gene expression of CPT-1A (arbitrary 
fluorescence units: EV 61.2±6.7 versus TSPO 119.8±2.5;  n=3; p< 0.01).   
The ability of TSPO overexpression (48h) to increase cholesterol efflux, and protect macrophages 
against accumulation of cholesteryl ester was investigated following exposure to AcLDL (50g ml-1) 
for 24h (Figures 4C and 4D).   Following a cholesterol load, apoA-I stimulated cholesterol efflux by 
1.9±0.2-fold (p<0.05) above basal (empty vector) control.   By contrast, in TSPO overexpressing 
cells, apoA-I increased cholesterol efflux by 3.8±0.4-fold (p<0.001), an increase of 1.6±0.1-fold 
(p<0.01) compared with the EV control (Figure 4C).    Equally, while addition of AcLDL (50g ml-1) 
increased incorporation of [
3
H]oleate into the cholesteryl ester pool by 81±12.0% (p<0.01, n=3) in 
macrophages transfected with the empty vector, overexpression of TSPO prevented significant 
increases in formation of cholesteryl [
3
H]oleate following treatment with this modified lipoprotein  
(Figure 4D, top panel).  Equally, TSPO overexpression effectively prevented the increase in 
cholesterol mass following AcLDL (50g ml-1; 24h) treatment (Figure 4D, bottom panel), compared 
with the empty vector control. A small decrease in expression of ACAT1 protein was noted in TSPO-
overexpressing cells (8.9± 1.8%; NS, n=3) (Figure 5B). 




Overexpression of TSPO: changes in expression of genes and proteins involved in the 
cholesterol efflux pathway 
Gene expression of the sterol responsive transcription factors, SREBF2, PPARD and PPARG were 
repressed in cells overexpressing TSPO, while expression of NR1H3 was significantly increased, this 
last reflected in increased LXRE reporter activity (TSPO 184.8±23.2% of control; p<0.05; n=4).  
Gene expression of PPARA (Figure 5A) was increased, accompanied by an increase in PPAR 
protein (32± 5.7%; p<0.05, n=3) in macrophages transiently expressing TSPO compared with 
GAPDH (Figure 5B).  Treatment with FGIN-1-27 (10M; 24h) also increased mRNA levels of 
PPARA (2.0±0.2-fold; n=3) and NR1H3 (1.5±0.5-fold; n=7), replicating observations in TSPO 
overexpressing macrophages.     
Increases in the expression of genes encoding proteins involved in the cholesterol efflux pathway 
were noted in macrophages overexpressing TSPO (Figure 5A).  Levels of ABCA1 mRNA increased 
by more than 6.5±2.3-fold (n=6), and this was reflected in increased levels of ABCA1 protein (39± 
9.3 %; p<0.05; n=3; Figure 5B) compared with GAPDH.  Gene expression of ABCG4 and the 
endogenously produced cholesterol acceptor, APOE, were also increased by 2 to 3-fold (n=6) in 
macrophages overexpressing TSPO (48h).  Analysis of an array of genes implicated in 
atherosclerosis, relative to five housekeeping genes, revealed only two more genes upregulated by >3-
fold following TSPO overexpression: FN1 and PDGFB.   
Overexpression and ligation of TSPO: blockade by PPAR antagonism 
Since induction of PPAR is implicated in the pathway by which TSPO overexpression or ligation 
stimulates the cholesterol efflux, a short series of experiments were performed using PPAR 
antagonists.  Induction of ABCA1 gene expression by TSPO (ratio to GAPDH: control 0.98 versus 
TSPO 2.45) was blocked by addition of 10M GW647126 (ratio to GAPDH: control 0.85 versus 
TSPO 0.98)  and partially reduced by treatment with GGPP
7
 (10M) (ratio to GAPDH: control 1.05 
versus TSPO 1.99).  Induction of NR1H3 by TSPO (ratio to GAPDH: control 1.14 versus TSPO 3.89) 
was effectively inhibited by both 10M GW6471 (ratio to GAPDH: control 0.58 versus TSPO 0.39) 
and 10M GGPP7 (ratio to GAPDH: control 0.10 versus TSPO 0.31); the values are averages from a 
single representative experiment, which was performed three times.    
Further, the stimulatory effect of TSPO overexpression on [
3
H]cholesterol efflux to apoA-I (20g ml-
1
; 24h) was effectively blocked by the addition of PPAR antagonist, GW647126 (10M) (Figure 6A) 
and by treatment with siRNA (10nM) directed against PPAR (Figure 6B), allow us to posit the 
pathway described in Figure 6C.   
 





This study investigated the relationship between components of the mitochondrial cholesterol 
trafficking and macrophage cholesterol homeostasis, and demonstrated that overexpression, gene 
silencing and ligation of mitochondrial TSPO modulate cholesterol efflux, with TSPO overexpression 
channelling cholesterol away from the cholesteryl ester pool and reducing macrophage total neutral 
lipid mass, without triggering compensatory increases in lipogenesis.    These effects appear to be 
related to the induction and/or activation of LXR and PPAR caused by TSPO overexpression or 
ligation: blockade of either pathway using antagonists and/or siRNA directed against these 
transcription factors prevented the TSPO-dependent increases in cholesterol efflux. 
Overexpression of the 18kDa translocator protein (TSPO) is associated with increased efflux of 
cholesterol to apoA-I and HDL, and induction of expression of genes involved in the cholesterol 
efflux pathway
7,8
, including NR1H3, ABCA1, ABCG4, but not ABCG1 (Figure 5).   The reason for 
this distinctive regulatory pattern is not clear at present, but dissociation of ABCA1 and ABCG1 gene 
expression has been noted in bovine mammary tissue during the switch from lactating to dry to 
periods
27
.  Induction of LXR is consistent with sequestration of SREBP2 protein at the endoplasmic 
reticulum, and loss of SREBF2 expression (Figure 5A):  both may contribute to increased induction 
of ABCA1 mRNA and protein
29-31
.   Expression of ABCG4 in human monocyte-macrophages lies 
under the control of oxysterols and retinoids
31
 suggesting this gene and ABCA1 may both be regulated 
by LXR activation or induction (Figure 5A), and one mechanism by which [3H]cholesterol efflux to 
HDL is increased (Figure 2B).   
Moreover, overexpression of TSPO and/or ligation of this protein by FGIN-1-27, induced PPAR 
alpha gene and/or protein levels, previously associated with increased ABCA1 expression and 
cholesterol efflux
32-35
.   Expression of PPAR can be regulated by stress, hormones and starvation in 
rodents, while human PPAR can mediate its own expression, and is induced during macrophage 
differentiation in response to high glucose levels
33
.  Notably, the PPARpromoter can be activated by 
PPAR agonists in an LXR dependent manner, and LXR is a PPAR target35, so that these 
transcription factors can work together in a cooperative manner to control ABCA1 expression and 
cholesterol efflux
32
.   Overexpression of TSPO induces expression of LXR and PPAR, while use of 
either SiRNA or an antagonist directed against PPAR (GW6471) (Figure 6) indicates an obligate 
role for PPAR in mediating TSPO-dependent increases in [3H]cholesterol efflux to apoA-I and 
possibly other cholesterol acceptors (Figure 2B).   
Indeed, the coordinated induction of PPAR and LXR by TSPO may be a key factor in abrogating 
the adverse effects previously associated with activation of LXR by agonists such as T09131736.  In 
particular, our previous study
7
, reported that overexpression and activation of mitochondrial 




cholesterol trafficking protein, StAR, in murine macrophages, was associated not only with enhanced 
cholesterol efflux and increased expression of ABCA1, but also with substantive induction of 
lipogenesis, thereby limiting the potential therapeutic utility of this approach
7, 36
.   By contrast, 
overexpression of TSPO was associated not only with increased cholesterol efflux to acceptors 
(Figure 2B) but with a marked loss of macrophage neutral lipid content (Fig 4A), and a small 
reduction in lipogenesis, primarily within the fatty acid pool (Fig 4B).  Further, and consistent with 
PPAR induction, levels of CPT-1A gene expression were increased, reflected in enhanced fatty acid 
oxidation, in TSPO overexpressing cells.   Activation of PPAR is known to induce modest increases 
in lipogenesis, possibly via participation in the generation of an endogenous LXR ligand35, and 
enhances fatty acid oxidation, by inducing the expression of long chain fatty acyl CoA synthetases 
and carnitine palmitoyl transferase-1, essential for generating fatty acyl CoA and facilitating the entry 
of fatty acyl carnitine into mitochondria for -oxidation32-34.  These data provide a plausible 
explanation for the observed reductions in macrophage triacylglycerol content (Figure 4A) and 
[
14
C]fatty acid levels (Fig 4B).  Overexpression of TSPO was also associated with reduced 
incorporation of [
3
H]oleate into the cholesteryl ester pool, and with decreased total cholesterol mass, 
following exposure to modified LDL (Fig 4D),  which may reflect the reduced availability of de novo 
synthesized fatty acids for esterification (Fig 4B)
32-34
;  indeed, activation of PPAR and LXR have 
previously been associated reductions in ACAT activity and cholesterol esterification in human 
macrophages
32,33
.   
Notably, treatment with acetylated LDL appears to reflect the induction of TSPO observed in human 





H]DAA1106 have been shown to significantly correlate with macrophage burden
37
. Lipid regulation 
of TSPO gene expression has not previously been reported during macrophage cholesterol loading, 
but Tspo can be regulated by protein kinase C by downstream signalling pathways involving 
mitogen-activated protein kinase MAPK (Raf-ERK1/2), and by acting on targets such as c-Jun, and 
the signal transducer and activator of transcription 3 (STAT3)
16,17
.  It is known that STAT3 gene 
delivery can reduce atherosclerotic lesions in LDL receptor knockout mice fed a high cholesterol 
diet
37
, but whether induction of TSPO forms part of that response is not established.   However, it is 
known that expression of TSPO is modulated by PPARs in a tissue specific manner, with 
transrepression of Tspo by PPAR cited in Leydig cells, but the reverse noted in non-steroidogenic 
tissues
17
.  Given the presence of a number of putative PPAR response elements within the promoter 
region of TSPO, it is possible to speculate that induction of PPAR in human macrophages may form 
part of a feed-forward regulatory loop, sustaining or amplifying TSPO expression (Figure 6).   
Finally, the ability of TSPO to moderate gene transcription, has been observed in lower species, and 
thus may be evolutionarily conserved in mammalian cells.  For example, the bacterial ortholog, TspO 




outer membrane protein, found in Rhodobacter sphaeroides, which is involved in effluxing 
intermediates of the porphyrin biosynthetic pathway, acts as a co-activator of transcription of a 
number of genes, encoding enzymes involved in photopigment biosynthesis
39,40
.  Arabidopsis TSPO is 
also linked to porphyrin metabolism, and appears to act as a signal linking water-related stress to 
transient increases in gene expression of the plant stress hormone, absicisc acid
41
.    
Summary 
We propose a model wherein a modest cholesterol load induces macrophage overexpression of TSPO 
mRNA and protein, facilitating cholesterol efflux to apoA-I, HDL and human serum, inducing the 
expression of NR1H3, PPARA, ABCA1, ABCG4 and APOE, and reducing macrophage cholesterol and 
triacylglycerol mass.  In turn, we speculate that loss of this protective TSPO-coordinated response, 
exemplified in Figure 6C, may be part of the pathophysiology of ‘foam cell’ formation; certainly, 
chronic high fat, high cholesterol supplementation, and associated oxidative stress, decreases TSPO 
binding capacity in rodent hepatic and aortic tissues
42
.  Targeting mitochondrial TSPO activity or 
maintaining its function could prove therapeutically useful in regressing atherosclerotic lesions, 
particularly since bioavailable TSPO ligands, without obvious side effects, are currently in 
development for other disease conditions
43
.   
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Figure Legends 
Figure Legends 
Figure 1 Gene expressions of components of the basal mitochondrial complex, TSPO, VDAC 
and ANT, relative to the housekeeping gene GAPDH, in human peripheral blood monocytes (PBMC; 
10
7
) and pooled human heart aortas (50g) (Materials and Methods) are shown in Figure 1A.  In each 
case, a single sample was analysed.  The levels of mRNA for TSPO (n=6), VDAC (n=5) and ANT 
(n=5).relative to the housekeeping gene GAPDH, in THP-1 macrophages (THP-1 Mand in THP-1 
macrophage ‘foam cells’ (THP-1 Foam Mgenerated by two consecutive treatments (24h) with 
50g ml-1 AcLDL, is shown in Figure 1B.  Values are mean±SEM, and significance between 
expression in macrophages and macrophage ‘foam’ cells was determined by Student’s t-test.  Figure 
1C shows AcLDL-induced expression of TSPO protein, relative to VDAC and GAPDH (n=3; 
*p<0.05) as assessed by ECL detection.   
Figure 2 Figure 2A shows the extent of overexpression (24h) of TSPO (0.5g pCMV_TSPO) 
compared with empty vector (EV) control; values are mean±SEM for n=3 experiments.  Figure 2B 
shows the knockdown (24h) of TSPO protein achieved using SiRNA (10nM) directed against TSPO, 
compared with scrambled SiRNA control (10nM); values are mean±SEM for n=3 experiments.  
Overexpression of TSPO was detected using ECL reagents, while the image for SiRNA knockdown 
of TSPO was generated using fluorescently labelled secondary antibodies and the LI-COR detection 




system (Methods). *p<0.05 indicates a significant difference from the EV and SiRNA controls, 
determined using Students’ t-test.   The effect of overexpression of TSPO protein, on the efflux (24h) 
of [
3
H]cholesterol to apoA-I (20g ml-1; n=3), HDL (20g ml-1; n=3) or human serum (1%, v/v; n=3) 
is shown in Figure 2C.  Figure 2D shows the effect of siRNA (10nM) directed against TSPO on efflux 
of [
3
H]cholesterol to apoA-I (20g ml-1; n=4) and HDL (20g ml-1; n=4).   Values are mean±SEM; 
significant differences due to genetic manipulation of TSPO were determined using Students’ t-test 
and are as indicated on Figure 2C and 2D.   
Figure 3 The effect of TSPO ligands, PK11195 (30M; n=3) and flunitrazepam (30M; n=3), 
on the efflux of [
3
H]cholesterol to apoA-I (20g ml-1) and HDL (20g ml-1) are shown in Figure 3A 
and 3B, respectively.   Figure 3C shows the effect of treatment with FGIN-1-27 (10M; n=3) on 
cholesterol efflux to ApoA-I and HDL at the same concentrations.    Significance levels in Fig3A to 
3C were determined using one-way ANOVA and Bonferroni post-test: *p<0.05; ***p<0.001 
compared with the control incubation; † p<0.05 and †† p<0.01 compared with apoA-I or HDL alone.  
Figure 3D shows efflux to apoA-I (20g ml-1), measured in the absence (n=6) or presence (n=3) of 
FGIN-1-27 (10M), in empty vector and TSPO overexpressing cells.  Significant differences between 
empty vector and TSPO overexpressing cells were determined using Student’s t-test. 
Figure 4 Figure 4A shows the effect of TSPO overexpression on macrophage triacylglycerol 
and total cholesterol mass; four independent experiments were performed, and statistical significance 
determined using Student’s t-test.  The impact of TSPO overexpression on nmol incorporation mg-1 
protein of [
14
C]acetate (1Ci ml-1) into phospholipid, triacylglycerol, cholesteryl ester, cholesterol and 
fatty acid lipid pools, compared with the empty vector (EV) control is shown in Figure 4B; n=6, with 
significance determined by Student’s t-test.   The efflux of cholesterol to apoA-I (20 g ml-1; 24h; 
n=4) in empty vector and TSPO-transfected macrophages previously exposed to a cholesterol load 
(AcLDL, 24h, 50g ml-1) is shown in Figure 4C; significant differences were determined by one way 
ANOVA and Bonferroni post-test.   The incorporation of  [
3
H]oleate (1Ci ml-1; 10M; n=3) into the 
cholesteryl ester pool in empty vector and TSPO transfected macrophages, and in the absence or 
presence of AcLDL (50g ml-1; 24h) is shown in the upper panel of Figure 4D, while the total 
cholesterol mass, investigated in the presence of AcLDL (50g ml-1; 24h; n=3), is shown in the lower 
panel of Figure 4D; significant differences were determined using one-way ANOVA and Bonferroni 
post t-test.  In all cases, *p<0.05, **p<0.01 or ***p|<0.001 compared with the relevant control 
incubation; other significant differences are indicated on each Figure. 
Figure 5 Fold changes in gene expression of lipid-responsive transcription factors in 
macrophages transiently expressing TSPO, relative to the empty vector (EV) control, are shown in 
Figure 5A.  Increased expressions of ABCA1 and PPAR, relative to ACAT1 and GAPDH, in TSPO- 




overexpressing cells, compared with EV controls, are shown in Figure 5B (n=3; *p<0.05).  The 
immunoblots for ABCA1 and ACAT1 were generated using ECL detection, while that for 
PPARutilised fluorescently labelled secondary antibody and LI-COR software (Methods). 
Figure 6 The impact of PPAR antagonist GW6471 (10M) on [3H]cholesterol efflux to 
apoA-I (20g ml-1; 24h; n=4), in empty vector (EV) and TSPO transfected macrophages is shown in 
Figure 6A.   Significant differences were determined by one-way ANOVA and Bonferroni post-test.  
Efflux to apoA-I (20g ml-1; 24h; n=3) in TSPO transfected macrophages simultaneously treated with 
either negative SiRNA (10nM) or SiRNA (10nM) directed against PPAR is shown in Figure 6B.   
Significance between negative SiRNA and PPAR SiRNA in TSPO transfected cells was determined 
by Student’s t-test.   In all cases, *p<0.05 compared with the empty vector control; other significant 
differences are indicated on the Figures.  Figure 6C shows a schematic model illustrating the putative 
pathways by which TSPO overexpression may interface with LXRand PPAR pathways to mediate 
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